Carcinoid tumor

This Phase II trial tests whether combining lenvatinib and everolimus can shrink or slow advanced carcinoid tumors that cannot be removed by surgery. The study enrolls 36 adults with confirmed unresectable carcinoid tumors. Both drugs are taken orally and work by blocking enzymes…

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…

This study tested a drug called pazopanib in 171 people with carcinoid tumors that were growing or spreading. The goal was to see if pazopanib could slow tumor growth better than a placebo. Participants were randomly assigned to receive either pazopanib or a placebo, and research…

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …

This phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…

This study is testing a custom-made artificial heart valve, called TRICENTO, in 15 people with carcinoid heart disease who have severe leakage of the tricuspid valve and cannot have surgery. The valve is delivered through a catheter, avoiding open-heart surgery. The goal is to se…

This early-phase study tests a new radioactive drug, [212Pb] VMT-α-NET, in 24 adults with advanced neuroendocrine tumors that have not responded to other treatments. The main goal is to find a safe dose for future studies, not to treat the disease. Participants receive up to two …

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

This study looks at whether a special type of CT scan, called dual energy CT, can better detect carcinoid tumors in the digestive system. About 71 people with signs or confirmed carcinoid tumors will get this scan during a routine check-up. The goal is to see if this imaging meth…

This study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the sca…

This study looks at two methods for keeping the lungs still during radiation treatment for lung cancer. One method uses a special camera system (SGRT) alone, and the other adds small implanted markers (fiducials) for extra guidance. The goal is to see which approach is more relia…

This registry is collecting blood samples and health data from 400 people with neuroendocrine tumors. The goal is to see if a new blood test called NETest can help detect tumor activity and predict disease progression. Participants include patients before and after surgery, those…